Patents by Inventor Ivan Alferiev
Ivan Alferiev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414766Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: ApplicationFiled: April 27, 2023Publication date: December 28, 2023Applicant: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Patent number: 11642414Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: GrantFiled: February 11, 2022Date of Patent: May 9, 2023Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Patent number: 11633485Abstract: A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1??(I) R—X—CO—O—CH2—CO—OR1??(II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.Type: GrantFiled: March 13, 2018Date of Patent: April 25, 2023Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur
-
Publication number: 20230048369Abstract: Compositions and methods for mitigating SVD mechanisms in BHV, including non-calcific SVD mechanisms, are provided.Type: ApplicationFiled: January 13, 2021Publication date: February 16, 2023Inventors: Giovanni Ferrari, Antonio Frasca, Yingfei Xue, Andrey Zakharchenko, Michael Chorny, Robert Levy, Ivan Alferiev
-
Publication number: 20220160886Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: ApplicationFiled: February 11, 2022Publication date: May 26, 2022Applicant: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Patent number: 11253603Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: GrantFiled: September 17, 2019Date of Patent: February 22, 2022Assignee: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Publication number: 20210000967Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.Type: ApplicationFiled: September 17, 2019Publication date: January 7, 2021Applicant: The Children's Hospital of PhiladelphiaInventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
-
Publication number: 20200061199Abstract: A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1??(I) R—X—CO—O—CH2—CO—OR1??(II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.Type: ApplicationFiled: March 13, 2018Publication date: February 27, 2020Inventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur
-
Patent number: 10058419Abstract: Oxidation resistant bioprosthetic tissues and oxidation resistant bioprosthetic heart valve leaflets are described. Also provided are methods for preparing the oxidation resistant bioprosthetic tissues and bioprosthetic heart valve leaflets, and methods for preventing oxidative degeneration in bioprosthetic tissues, including immobilizing covalently an effective amount of an antioxidant to the bioprosthetic tissue.Type: GrantFiled: July 11, 2012Date of Patent: August 28, 2018Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Ivan Alferiev, Stanley Stachelek, Jeanne M. Connolly, Abigail Christian
-
Patent number: 9694103Abstract: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.Type: GrantFiled: September 7, 2012Date of Patent: July 4, 2017Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Ilia Fishbein, Michael Chorny, Robert J. Levy, Benjamin Yellen, Darryl Williams
-
Patent number: 9233163Abstract: A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.Type: GrantFiled: December 28, 2011Date of Patent: January 12, 2016Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Michael Chorny, Robert J. Levy
-
Patent number: 9095610Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.Type: GrantFiled: September 30, 2013Date of Patent: August 4, 2015Assignees: CHILDREN'S HOSPITAL OF PHILADELPHIA, DREXEL UNIVERSITYInventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams
-
Publication number: 20150119388Abstract: An ester of ArOH according to the formula R—X—CO—OAr, wherein ArOH is a pharmaceutically active compound selected from the group consisting of SN-38, PI-103, etoposide and fenretinide, wherein a) R is a residue of cholesterol, sitosterol, SN-38, PI-103, etoposide or fenretinide and X is O—CO-L, wherein L is either a direct bond or a linking group including a branched or unbranched hydrocarbyl moiety that may optionally include in-chain or pendant heteroatom substituents and/or cyclic moieties; b) R—X—CO-0 is an all-trans retinoate radical or the 9-cis or 13-cis isomer thereof; or c) R—X— is a branched or unbranched, saturated or unsaturated hydrocarbyl moiety comprising at least 5 carbon atoms and optionally including at least one in-chain or pendant heteroatom substituent and/or cyclic moiety.Type: ApplicationFiled: June 14, 2013Publication date: April 30, 2015Applicant: THE CHILDREN'S HOSPITAL PHILADELPHIAInventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur, Robert J. Levy
-
Publication number: 20140288641Abstract: Oxidation resistant bioprosthetic tissues and oxidation resistant bioprosthetic heart valve leaflets are described. Also provided are methods for preparing the oxidation resistant bioprosthetic tissues and bioprosthetic heart valve leaflets, and methods for preventing oxidative degeneration in bioprosthetic tissues, including immobilizing covalently an effective amount of an antioxidant to the bioprosthetic tissue.Type: ApplicationFiled: July 11, 2012Publication date: September 25, 2014Applicant: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Ivan Alferiev, Stanley Stachelek, Jeanne M. Connolly, Abigail Christian
-
Publication number: 20140170201Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.Type: ApplicationFiled: September 30, 2013Publication date: June 19, 2014Applicants: Drexel University, The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams
-
Photo-activated attachment of cholesterol to polyurethane surfaces for adhesion of endothelial cells
Patent number: 8618242Abstract: A polymer is provided according to structure I wherein Y is a thiol-reactive group and Z is an ionogenic group. The surface of a polymeric substrate is modified by contacting the surface with a polymer according to structure II or structure III and exposing the surface to ultraviolet light, optionally followed by contacting the modified surface with the polymer according to structure I.Type: GrantFiled: April 9, 2010Date of Patent: December 31, 2013Assignee: The Children's Hospital of PhiladelphiaInventors: Robert J. Levy, Ivan Alferiev, Stanley J. Stachelek -
Patent number: 8580545Abstract: A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate is covalently bound to the biodegradable cross-linker portion, provided that the biodegradable cross-linker is adapted to hydrolyze by breaking the hydrolyzable bond and thereby release and deliver the biomaterial. A process of making the composition is also provided.Type: GrantFiled: November 29, 2011Date of Patent: November 12, 2013Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Robert J. Levy, Ilia Fishbein
-
Publication number: 20130296285Abstract: A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.Type: ApplicationFiled: December 28, 2011Publication date: November 7, 2013Applicant: THE CHILDRENS HOSPITAL OF PHILADELPHIAInventors: Ivan Alferiev, Michael Chorny, Robert J. Levy
-
Patent number: 8562505Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.Type: GrantFiled: May 1, 2008Date of Patent: October 22, 2013Assignees: The Children's Hospital of Philadelphia, Drexel UniversityInventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ivan Alferiev, Gennady Friedman, Darryl Williams, Ilia Fishbein
-
Publication number: 20130243862Abstract: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.Type: ApplicationFiled: September 7, 2012Publication date: September 19, 2013Applicant: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Ilia Fishbein, Michael Chorny, Robert J. Levy, Benjamin Yellen, Darryl Williams